MediWound Ltd

MediWound Ltd is a biotechnology company based in Israel that specializes in developing innovative treatments for severe burns and chronic wounds. The company was founded in 2001 by Dr. Lior Rosenberg, a leading plastic surgeon and burn specialist, who recognized the need for better solutions for wound care. MediWound's headquarters are located in Yavne, Israel, and its shares are traded on the Nasdaq Stock Market under the symbol MDWD. As of May 10, 2023, the company had a market cap of $79.0 million.

MediWound's vision is to improve the quality of life of patients suffering from severe and hard-to-heal wounds and to reduce the burden on the healthcare system. The company's flagship product, NexoBrid, is a topical gel that removes dead tissue from burn wounds without harming healthy tissue. NexoBrid has been approved by the European Medicines Agency (EMA) and the Israeli Ministry of Health and is currently undergoing a phase 3 clinical trial in the United States. NexoBrid has been used to treat over 7,000 patients in more than 40 countries and has demonstrated superior clinical outcomes compared to the standard of care.

In addition to its product pipeline, MediWound has received several awards and recognitions for its achievements and innovations. In 2019, the company won the Frost & Sullivan European Technology Innovation Award for its enzyme-based wound care products. In 2020, the company was selected as one of the Red Herring Top 100 Europe companies and was ranked among the top 10 Israeli biotech companies by Globes. In 2021, the company received the Galien Foundation Prix Galien Israel Award for NexoBrid.

Foundation: 2001
Headquarters: Yavne, Israel
Website: https://www.mediwound.com/